Philip Morris International Progresses Towards Smoke-Free Future

Sep.16.2022
Philip Morris International Progresses Towards Smoke-Free Future
PMI aims to end cigarette sales and promote smoke-free alternatives, with decreasing sales and increasing investment in innovation products.

PMI is often asked if it truly intends to end cigarette sales.


The answer is: yes.


Philip Morris International acknowledges that the decline in cigarette sales - or broadly speaking, the decline in the combustible product portfolio of PMI - is a necessary component in achieving its ambitions for a smoke-free future.


Fimo International is rapidly making progress towards this goal.


According to data publicly released by Fumo International, their cigarette sales have been on a downward trend for the past decade.


The annual sales volume of cigarettes has declined from 91.5 billion units in 2011 to 62.5 billion units in 2021, decreasing every year over the past nine years.


Furthermore, PMI has set a target for the total shipment of combustible products to be below 550 billion units by 2025, as stated in their 2021 comprehensive report.


The cigarette shipments of PMI (Phillip Morris International) have decreased from 915 billion in 2011 to 625 billion in 2021.


Phimo International aims to ultimately replace cigarettes with smoke-free alternatives.


Since 2008, Philip Morris International has invested over 9 billion dollars in the research and development, product development, production capabilities, scientific validation, and understanding of adult smokers for these innovative products.


This is a successful investment as an increasing number of adult smokers are switching to FiMO International's heated tobacco products, leading to a reduction in cigarette transportation volume.


As of June 30th, 2022, approximately 13.2 million adult smokers have switched to smoke-free alternatives and quit smoking.


The shipment volume of PhiMo International's heated tobacco devices has increased from 7 billion in 2016 to 95 billion in 2021.


These figures are transparently released annually by Fimo International for anyone to access.


Although the optimal choice for any smoker is to completely quit smoking and nicotine, scientifically proven smokeless products are a better option for adult smokers who would otherwise continue smoking.


According to Moira Gilchrist, VP of Strategic and Scientific Communication at Philip Morris International, the company's decision to unilaterally stop selling cigarettes tomorrow will not change anything. "Because it doesn't eliminate the demand for cigarettes. The demand will remain, and others will simply fill it, whether it be competitors or participants in the black market.


Our transition is more significant because we are striving to reduce the long-term demand for cigarettes, ensuring that the decline in the number of smokers continues - and may even accelerate further.


These numbers cannot be ignored," said Stefano Volpetti, President of the PMI Smoke-Free Products category and Chief Consumer Officer. "They clearly depict the transformation that Philip Morris International is driving - first, providing a range of better alternatives for adult smokers and secondly, accelerating smoking cessation.


Our scientific evidence confirms that PMI's smoke-free products, while not without risk, are a better choice than cigarettes for adults who would otherwise continue to smoke.


With support from the industry, stakeholders, and civil society, we believe that cigarette sales can come to an end in many countries within 10 to 15 years. This would be an enduring achievement for the global population of 1 billion smokers, global public health, and our company.


As of June 30, 2022, Philip Morris International (PMI) estimates that approximately 13.2 million adult individuals worldwide (excluding Russia and Ukraine) have switched to their heated tobacco products and quit smoking. These user statistics are reflective of PMI's estimates, which are based on consumer statements and sample-based statistical evaluations, with an average margin of error of +/-5% within the 95% confidence interval in key quantity markets. The accuracy and reliability of user statistics may vary depending on the maturity of individual markets and the availability of information.


Statement:


The content of this article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The translation of this article is for industry exchange and research purposes only.


Due to the limitations of the translator's skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS’ viewpoints and statements on any domestic, Hong Kong, Macau, Taiwan, or international issues are entirely aligned with those of the Chinese government.


The copyright of compiled information belongs to the original media outlet and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
DOJO launched the BLAST10K Fresh in the UK on September 4, 2026, introducing its INSTA-JUICED™ technology and a new 0+10ml structure that keeps e-liquid separated from the coil before activation. The device features a 1000mAh rechargeable battery, COREX BLAST dual-mesh technology and SSS leak-resistant technology, with a manufacturer-rated capacity of up to 10,000 puffs. It also retains compatibility with existing 2+8ml pods across the BLAST ecosystem. The launch introduces eight new flavors, including Matcha Strawberry, which DOJO describes as an industry first.
Market
Sep.04
Gallery | InterTabac 2026 Opens as VAPORESSO, SKE, GREENTANK, GEEK BAR and Other Brands Take the Floor
Gallery | InterTabac 2026 Opens as VAPORESSO, SKE, GREENTANK, GEEK BAR and Other Brands Take the Floor
InterTabac 2026 opened in Dortmund, Germany, on September 15 alongside NUBIZ and InterSupply. According to the latest figures released by the organizer, the three trade shows bring together around 750 exhibitors from 64 countries. On site, 2Firsts observed vaping and related brands including VAPORESSO, DOJO, SKE, GREENTANK, GEEK BAR, HQD and ELUX.
Special Report
Sep.15
 PMI Opens Generative AI Center in Portugal to Support Global Operations
PMI Opens Generative AI Center in Portugal to Support Global Operations
According to information released by Portugal’s Trade & Investment Agency (AICEP) in July 2026, Philip Morris International (PMI) has established a global Generative Artificial Intelligence Factory (GenAI Factory) at its Portuguese subsidiary Tabaqueira. The center will support PMI’s global operations by developing and deploying AI solutions focused on industrial process optimization, data analytics, operational automation and AI application development. The initiative strengthens Portugal’s role in PMI’s global technology and innovation network.
Aug.27
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22